OverviewChartNewsTraderScreen

Soc. Generale Call 56 BMY 16.01.2.../  DE000SW9CVU2  /

EUWAX
2024-06-06  10:05:17 AM Chg.-0.020 Bid6:41:17 PM Ask6:41:17 PM Underlying Strike price Expiration date Option type
0.180EUR -10.00% 0.180
Bid Size: 400,000		 0.190
Ask Size: 400,000		 Bristol Myers Squibb... 56.00 USD 2026-01-16 Call
GlobeNewswire 05-31 Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting P...
GlobeNewswire 05-30 Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire 05-24 Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
GlobeNewswire 05-23 Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire 05-23 Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Pr...
GlobeNewswire 05-22 CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewswire 05-22 Anavex Life Sciences Announces Expansion of Leadership Team
GlobeNewswire 05-16 CytomX Therapeutics Announces New Employment Inducement Grants
GlobeNewswire 05-15 Lantheus Announces Executive Appointments to Accelerate Innovation
GlobeNewswire 05-14 Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Healthcare-Industry Executive, Dav...
GlobeNewswire 05-14 Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire 05-13 Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire 05-08 CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 05-08 Immunocore reports first quarter financial results and provides a business update
GlobeNewswire 05-07 CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire 05-02 Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., ...
GlobeNewswire 05-01 Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
GlobeNewswire 05-01 CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire 04-30 Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
GlobeNewswire 04-30 CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical D...
GlobeNewswire 04-25 International Myeloma Foundation Holds 15th Annual Gala at the Edison Ballroom in New York City on A...
GlobeNewswire 04-25 Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract ...
GlobeNewswire 04-25 Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...
GlobeNewswire 04-22 ArriVent Appoints Kristine Peterson to its Board of Directors
GlobeNewswire 04-08 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Sq...